Please assess the completion status of the following clinical trial:

Trial Title: Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HCV genotype 1 infection (all subtypes and Q80K a type of mutation are allowed), and have been approved by a third party payer for the FDA-approved combination of sofosbuvir (SOF) plus ribavirin. The study drug, simeprevir (SMV)~2. Biopsy proven cirrhosis, or clinical cirrhosis with APRI (AST to Platelet Ratio Index to determine clinical cirrhosis)\> 2, Fibrotest \> 0.75, or Fibroscan \> 12.5 Results Stiffness (kPa).~3. MELD 10 or less~4. Expected survival without liver transplantation of \>1 year~5. Patients with Hepatocellular carcinoma (HCC) are included as long as disease MELD is 10 or less, and anticipated time to transplant is \>1 year. An example, might be a patient with a subcentimeter HCC who is undergoing serial imaging to document tumor growth to tumor diameter \>2 cm prior to listing for transplantation (in order to secure MELD exception). In this case, there could be a time lapse of 3 months or more while monitoring tumor growth, and a further time lapse of 9 months or more until the time of transplantation.~6. Patients with TIPS or Portal Vein Thrombosis may be included. -~Exclusion Criteria:~1. Inability to provide informed consent~2. Known hypersensitivity or serious adverse reaction to any of the study drugs~3. Age \<18 or \>80 years~4. Pregnancy as determined by subject reporting and urine dipstick testing at screening.~5. Other underlying chronic liver disease - examples that would exclude a patient from participating include but are not limited to nonalcoholic liver disease, alcoholic liver disease, hepatitis B, hemochromatosis, and autoimmune liver disease.~6. Serious other underlying medical condition - examples include but are not limited to unstable cardiovascular, coronary, or pulmonary disease including right and left sided heart failure, active malignancy other than HCC, or serious infection.~7. Estimated creatinine clearance \< 30 mL min-1 1.73 m2 surface area (BSA)~8. Hemoglobin \<10 g/dL~9. Neutrophils \<500 /μL~10. Platelets \<50,000 /μL~11. Bilirubin \>4 mg/dL~12. Albumin \< 2.8 g/dL~13. Blood Clotting: International Normalised Ratio (INR) \> 2~14. MELD \>10~15. Child-Turcotte-Pugh class B or C; or, CTP score \>7~16. Conditions that would affect the absorption of orally administered cholate used in the HepQuant® test - such as, extensive intestinal resection, diabetic gastroparesis, and ileal disease or resection.~17. Concomitant use of both beta-blocker and ACE inhibitor~18. Subjects taking any other medications with significant drug drug interactions related to the study medications (sofosbuvir, simeprevir, or ribavirin) who cannot discontinue or substitute that medication, will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HCV positive group (Type: EXPERIMENTAL): A single arm study of 'Simeprivir (SMV), Sofosbuvir (SOF) and Ribavirin (RBV) in an HCV positive population.

Based on this trial design, predict the completion outcome and termination type (if applicable).